# Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis

> **NCT01318902** · PHASE1 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 27 (actual)

## Conditions studied

- Light-Chain Amyloidosis

## Interventions

- **DRUG:** Ixazomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01318902
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04-27
- **Primary completion:** 2018-11-13
- **Final completion:** 2018-11-13
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2020-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01318902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01318902, "Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01318902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*